18/09/2025
💨 每天鼻噴劑展現出對抗新冠病毒的驚人力量—還有更多
簡單的過處式鼻腔噴劑,全球已經用於過敏,也可能預防新冠病毒。
在德國薩爾蘭大學領導的第二階段臨床試驗中,研究人員測試了70多個國家可用的藥物。 超過八周,使用噴霧的人中只有2.2%感染新冠肺炎,而安慰劑群的6.7%。 這是減少三分之二的病例。
更耐人尋味的是,Azelastine似乎是減少症狀感染、呼吸道疾病,甚至是犀牛病毒(普遍感冒),暗示著更廣泛的抗病毒作用。 科學家認為噴霧是通過直接阻擋病毒複製在鼻子和上層氣道上 - 大多數呼吸道病原體的進入點。
由於它已經獲准患有花粉熱和過敏,所以azelastine可以成為一個可取得、低成本的預防選擇。 雖然它尚未獲得授權作為新冠病毒治療方法,但研究人員表示,它可能對脆弱人士和呼吸道感染季節性激增期間特別有用。 現在需要更大的多中心研究來確認這些結果。
📖 來源:
Lehr T、Meiser P、Selzer D、等人。 Azelastine 鼻腔噴霧,預防 SARS-CoV-2 感染:第二階段隨機臨床試驗。 JAMA內科,2025年9月2日。
#尼斯可 #噴鼻液
💨 Everyday nasal spray shows surprising power against COVID—and more
A simple over-the-counter nasal spray, already used worldwide for allergies, may also protect against COVID-19.
In a phase 2 clinical trial led by Saarland University, Germany, researchers tested azelastine, a medication available in more than 70 countries. Over eight weeks, only 2.2% of people using the spray contracted COVID-19—compared to 6.7% in the placebo group. That’s a two-thirds reduction in cases.
Even more intriguing, azelastine also appeared to reduce symptomatic infections, respiratory illnesses, and even rhinoviruses (the common cold), hinting at broader antiviral effects. Scientists think the spray works by blocking viral replication directly in the nose and upper airways—the entry point for most respiratory pathogens.
Because it’s already approved for hay fever and allergies, azelastine could become an accessible, low-cost preventive option. While it’s not yet authorized as a COVID treatment, researchers say it may be especially useful for vulnerable individuals and during seasonal surges of respiratory infections. Larger, multicenter studies are now needed to confirm these results.
📖 Source:
Lehr T, Meiser P, Selzer D, et al. Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial. JAMA Internal Medicine, September 2, 2025.
